
Global Pre-Exposure Prophylaxis (PrEP) Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Pre-Exposure Prophylaxis (PrEP) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Pre-Exposure Prophylaxis (PrEP) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Pre-Exposure Prophylaxis (PrEP) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Pre-Exposure Prophylaxis (PrEP) market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Pre-Exposure Prophylaxis (PrEP) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Pre-Exposure Prophylaxis (PrEP) market include Amneal Pharmaceuticals, Aurobindo Pharma, Gilead Sciences, Mylan, Teva, ViiV Healthcare, Zydus, Anhui Baker Biopharmaceutical and Chengdu Brilliant Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Pre-Exposure Prophylaxis (PrEP), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Pre-Exposure Prophylaxis (PrEP), also provides the sales of main regions and countries. Of the upcoming market potential for Pre-Exposure Prophylaxis (PrEP), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Pre-Exposure Prophylaxis (PrEP) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Pre-Exposure Prophylaxis (PrEP) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Pre-Exposure Prophylaxis (PrEP) sales, projected growth trends, production technology, application and end-user industry.
Pre-Exposure Prophylaxis (PrEP) Segment by Company
Amneal Pharmaceuticals
Aurobindo Pharma
Gilead Sciences
Mylan
Teva
ViiV Healthcare
Zydus
Anhui Baker Biopharmaceutical
Chengdu Brilliant Pharmaceutical
North China Pharmaceutical
Qilu Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Pre-Exposure Prophylaxis (PrEP) Segment by Type
Oral PrEP
Injectable PrEP
Pre-Exposure Prophylaxis (PrEP) Segment by Application
Hospital and Clinic
Pharmacy
Other
Pre-Exposure Prophylaxis (PrEP) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Pre-Exposure Prophylaxis (PrEP) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Pre-Exposure Prophylaxis (PrEP) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Pre-Exposure Prophylaxis (PrEP) significant trends, drivers, influence factors in global and regions.
6. To analyze Pre-Exposure Prophylaxis (PrEP) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pre-Exposure Prophylaxis (PrEP) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pre-Exposure Prophylaxis (PrEP) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pre-Exposure Prophylaxis (PrEP).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Pre-Exposure Prophylaxis (PrEP) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pre-Exposure Prophylaxis (PrEP) industry.
Chapter 3: Detailed analysis of Pre-Exposure Prophylaxis (PrEP) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Pre-Exposure Prophylaxis (PrEP) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Pre-Exposure Prophylaxis (PrEP) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, the global Pre-Exposure Prophylaxis (PrEP) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Pre-Exposure Prophylaxis (PrEP) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Pre-Exposure Prophylaxis (PrEP) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Pre-Exposure Prophylaxis (PrEP) market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Pre-Exposure Prophylaxis (PrEP) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Pre-Exposure Prophylaxis (PrEP) market include Amneal Pharmaceuticals, Aurobindo Pharma, Gilead Sciences, Mylan, Teva, ViiV Healthcare, Zydus, Anhui Baker Biopharmaceutical and Chengdu Brilliant Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Pre-Exposure Prophylaxis (PrEP), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Pre-Exposure Prophylaxis (PrEP), also provides the sales of main regions and countries. Of the upcoming market potential for Pre-Exposure Prophylaxis (PrEP), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Pre-Exposure Prophylaxis (PrEP) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Pre-Exposure Prophylaxis (PrEP) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Pre-Exposure Prophylaxis (PrEP) sales, projected growth trends, production technology, application and end-user industry.
Pre-Exposure Prophylaxis (PrEP) Segment by Company
Amneal Pharmaceuticals
Aurobindo Pharma
Gilead Sciences
Mylan
Teva
ViiV Healthcare
Zydus
Anhui Baker Biopharmaceutical
Chengdu Brilliant Pharmaceutical
North China Pharmaceutical
Qilu Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Pre-Exposure Prophylaxis (PrEP) Segment by Type
Oral PrEP
Injectable PrEP
Pre-Exposure Prophylaxis (PrEP) Segment by Application
Hospital and Clinic
Pharmacy
Other
Pre-Exposure Prophylaxis (PrEP) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Pre-Exposure Prophylaxis (PrEP) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Pre-Exposure Prophylaxis (PrEP) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Pre-Exposure Prophylaxis (PrEP) significant trends, drivers, influence factors in global and regions.
6. To analyze Pre-Exposure Prophylaxis (PrEP) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pre-Exposure Prophylaxis (PrEP) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pre-Exposure Prophylaxis (PrEP) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pre-Exposure Prophylaxis (PrEP).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Pre-Exposure Prophylaxis (PrEP) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pre-Exposure Prophylaxis (PrEP) industry.
Chapter 3: Detailed analysis of Pre-Exposure Prophylaxis (PrEP) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Pre-Exposure Prophylaxis (PrEP) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Pre-Exposure Prophylaxis (PrEP) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
191 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Pre-Exposure Prophylaxis (PrEP) Sales Value (2020-2031)
- 1.2.2 Global Pre-Exposure Prophylaxis (PrEP) Sales Volume (2020-2031)
- 1.2.3 Global Pre-Exposure Prophylaxis (PrEP) Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Pre-Exposure Prophylaxis (PrEP) Market Dynamics
- 2.1 Pre-Exposure Prophylaxis (PrEP) Industry Trends
- 2.2 Pre-Exposure Prophylaxis (PrEP) Industry Drivers
- 2.3 Pre-Exposure Prophylaxis (PrEP) Industry Opportunities and Challenges
- 2.4 Pre-Exposure Prophylaxis (PrEP) Industry Restraints
- 3 Pre-Exposure Prophylaxis (PrEP) Market by Company
- 3.1 Global Pre-Exposure Prophylaxis (PrEP) Company Revenue Ranking in 2024
- 3.2 Global Pre-Exposure Prophylaxis (PrEP) Revenue by Company (2020-2025)
- 3.3 Global Pre-Exposure Prophylaxis (PrEP) Sales Volume by Company (2020-2025)
- 3.4 Global Pre-Exposure Prophylaxis (PrEP) Average Price by Company (2020-2025)
- 3.5 Global Pre-Exposure Prophylaxis (PrEP) Company Ranking (2023-2025)
- 3.6 Global Pre-Exposure Prophylaxis (PrEP) Company Manufacturing Base and Headquarters
- 3.7 Global Pre-Exposure Prophylaxis (PrEP) Company Product Type and Application
- 3.8 Global Pre-Exposure Prophylaxis (PrEP) Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Pre-Exposure Prophylaxis (PrEP) Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Pre-Exposure Prophylaxis (PrEP) Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Pre-Exposure Prophylaxis (PrEP) Market by Type
- 4.1 Pre-Exposure Prophylaxis (PrEP) Type Introduction
- 4.1.1 Oral PrEP
- 4.1.2 Injectable PrEP
- 4.2 Global Pre-Exposure Prophylaxis (PrEP) Sales Volume by Type
- 4.2.1 Global Pre-Exposure Prophylaxis (PrEP) Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Pre-Exposure Prophylaxis (PrEP) Sales Volume by Type (2020-2031)
- 4.2.3 Global Pre-Exposure Prophylaxis (PrEP) Sales Volume Share by Type (2020-2031)
- 4.3 Global Pre-Exposure Prophylaxis (PrEP) Sales Value by Type
- 4.3.1 Global Pre-Exposure Prophylaxis (PrEP) Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Pre-Exposure Prophylaxis (PrEP) Sales Value by Type (2020-2031)
- 4.3.3 Global Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type (2020-2031)
- 5 Pre-Exposure Prophylaxis (PrEP) Market by Application
- 5.1 Pre-Exposure Prophylaxis (PrEP) Application Introduction
- 5.1.1 Hospital and Clinic
- 5.1.2 Pharmacy
- 5.1.3 Other
- 5.2 Global Pre-Exposure Prophylaxis (PrEP) Sales Volume by Application
- 5.2.1 Global Pre-Exposure Prophylaxis (PrEP) Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Pre-Exposure Prophylaxis (PrEP) Sales Volume by Application (2020-2031)
- 5.2.3 Global Pre-Exposure Prophylaxis (PrEP) Sales Volume Share by Application (2020-2031)
- 5.3 Global Pre-Exposure Prophylaxis (PrEP) Sales Value by Application
- 5.3.1 Global Pre-Exposure Prophylaxis (PrEP) Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Pre-Exposure Prophylaxis (PrEP) Sales Value by Application (2020-2031)
- 5.3.3 Global Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application (2020-2031)
- 6 Pre-Exposure Prophylaxis (PrEP) Regional Sales and Value Analysis
- 6.1 Global Pre-Exposure Prophylaxis (PrEP) Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Pre-Exposure Prophylaxis (PrEP) Sales by Region (2020-2031)
- 6.2.1 Global Pre-Exposure Prophylaxis (PrEP) Sales by Region: 2020-2025
- 6.2.2 Global Pre-Exposure Prophylaxis (PrEP) Sales by Region (2026-2031)
- 6.3 Global Pre-Exposure Prophylaxis (PrEP) Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Pre-Exposure Prophylaxis (PrEP) Sales Value by Region (2020-2031)
- 6.4.1 Global Pre-Exposure Prophylaxis (PrEP) Sales Value by Region: 2020-2025
- 6.4.2 Global Pre-Exposure Prophylaxis (PrEP) Sales Value by Region (2026-2031)
- 6.5 Global Pre-Exposure Prophylaxis (PrEP) Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Pre-Exposure Prophylaxis (PrEP) Sales Value (2020-2031)
- 6.6.2 North America Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Pre-Exposure Prophylaxis (PrEP) Sales Value (2020-2031)
- 6.7.2 Europe Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Pre-Exposure Prophylaxis (PrEP) Sales Value (2020-2031)
- 6.9.2 South America Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Pre-Exposure Prophylaxis (PrEP) Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Country, 2024 VS 2031
- 7 Pre-Exposure Prophylaxis (PrEP) Country-level Sales and Value Analysis
- 7.1 Global Pre-Exposure Prophylaxis (PrEP) Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Pre-Exposure Prophylaxis (PrEP) Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Pre-Exposure Prophylaxis (PrEP) Sales by Country (2020-2031)
- 7.3.1 Global Pre-Exposure Prophylaxis (PrEP) Sales by Country (2020-2025)
- 7.3.2 Global Pre-Exposure Prophylaxis (PrEP) Sales by Country (2026-2031)
- 7.4 Global Pre-Exposure Prophylaxis (PrEP) Sales Value by Country (2020-2031)
- 7.4.1 Global Pre-Exposure Prophylaxis (PrEP) Sales Value by Country (2020-2025)
- 7.4.2 Global Pre-Exposure Prophylaxis (PrEP) Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.9.2 France Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.16.2 China Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.19.2 India Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Pre-Exposure Prophylaxis (PrEP) Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Pre-Exposure Prophylaxis (PrEP) Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Amneal Pharmaceuticals
- 8.1.1 Amneal Pharmaceuticals Comapny Information
- 8.1.2 Amneal Pharmaceuticals Business Overview
- 8.1.3 Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Amneal Pharmaceuticals Pre-Exposure Prophylaxis (PrEP) Product Portfolio
- 8.1.5 Amneal Pharmaceuticals Recent Developments
- 8.2 Aurobindo Pharma
- 8.2.1 Aurobindo Pharma Comapny Information
- 8.2.2 Aurobindo Pharma Business Overview
- 8.2.3 Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Aurobindo Pharma Pre-Exposure Prophylaxis (PrEP) Product Portfolio
- 8.2.5 Aurobindo Pharma Recent Developments
- 8.3 Gilead Sciences
- 8.3.1 Gilead Sciences Comapny Information
- 8.3.2 Gilead Sciences Business Overview
- 8.3.3 Gilead Sciences Pre-Exposure Prophylaxis (PrEP) Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Gilead Sciences Pre-Exposure Prophylaxis (PrEP) Product Portfolio
- 8.3.5 Gilead Sciences Recent Developments
- 8.4 Mylan
- 8.4.1 Mylan Comapny Information
- 8.4.2 Mylan Business Overview
- 8.4.3 Mylan Pre-Exposure Prophylaxis (PrEP) Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Mylan Pre-Exposure Prophylaxis (PrEP) Product Portfolio
- 8.4.5 Mylan Recent Developments
- 8.5 Teva
- 8.5.1 Teva Comapny Information
- 8.5.2 Teva Business Overview
- 8.5.3 Teva Pre-Exposure Prophylaxis (PrEP) Sales, Value and Gross Margin (2020-2025)
- 8.5.4 Teva Pre-Exposure Prophylaxis (PrEP) Product Portfolio
- 8.5.5 Teva Recent Developments
- 8.6 ViiV Healthcare
- 8.6.1 ViiV Healthcare Comapny Information
- 8.6.2 ViiV Healthcare Business Overview
- 8.6.3 ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) Sales, Value and Gross Margin (2020-2025)
- 8.6.4 ViiV Healthcare Pre-Exposure Prophylaxis (PrEP) Product Portfolio
- 8.6.5 ViiV Healthcare Recent Developments
- 8.7 Zydus
- 8.7.1 Zydus Comapny Information
- 8.7.2 Zydus Business Overview
- 8.7.3 Zydus Pre-Exposure Prophylaxis (PrEP) Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Zydus Pre-Exposure Prophylaxis (PrEP) Product Portfolio
- 8.7.5 Zydus Recent Developments
- 8.8 Anhui Baker Biopharmaceutical
- 8.8.1 Anhui Baker Biopharmaceutical Comapny Information
- 8.8.2 Anhui Baker Biopharmaceutical Business Overview
- 8.8.3 Anhui Baker Biopharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Anhui Baker Biopharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Portfolio
- 8.8.5 Anhui Baker Biopharmaceutical Recent Developments
- 8.9 Chengdu Brilliant Pharmaceutical
- 8.9.1 Chengdu Brilliant Pharmaceutical Comapny Information
- 8.9.2 Chengdu Brilliant Pharmaceutical Business Overview
- 8.9.3 Chengdu Brilliant Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Chengdu Brilliant Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Portfolio
- 8.9.5 Chengdu Brilliant Pharmaceutical Recent Developments
- 8.10 North China Pharmaceutical
- 8.10.1 North China Pharmaceutical Comapny Information
- 8.10.2 North China Pharmaceutical Business Overview
- 8.10.3 North China Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Value and Gross Margin (2020-2025)
- 8.10.4 North China Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Portfolio
- 8.10.5 North China Pharmaceutical Recent Developments
- 8.11 Qilu Pharmaceutical
- 8.11.1 Qilu Pharmaceutical Comapny Information
- 8.11.2 Qilu Pharmaceutical Business Overview
- 8.11.3 Qilu Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Value and Gross Margin (2020-2025)
- 8.11.4 Qilu Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Portfolio
- 8.11.5 Qilu Pharmaceutical Recent Developments
- 8.12 Chia Tai Tianqing Pharmaceutical
- 8.12.1 Chia Tai Tianqing Pharmaceutical Comapny Information
- 8.12.2 Chia Tai Tianqing Pharmaceutical Business Overview
- 8.12.3 Chia Tai Tianqing Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Chia Tai Tianqing Pharmaceutical Pre-Exposure Prophylaxis (PrEP) Product Portfolio
- 8.12.5 Chia Tai Tianqing Pharmaceutical Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Pre-Exposure Prophylaxis (PrEP) Value Chain Analysis
- 9.1.1 Pre-Exposure Prophylaxis (PrEP) Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Pre-Exposure Prophylaxis (PrEP) Sales Mode & Process
- 9.2 Pre-Exposure Prophylaxis (PrEP) Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Pre-Exposure Prophylaxis (PrEP) Distributors
- 9.2.3 Pre-Exposure Prophylaxis (PrEP) Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.